首页> 外文期刊>Trials >Case management for patients with chronic systolic heart failure in primary care: The HICMan exploratory randomised controlled trial
【24h】

Case management for patients with chronic systolic heart failure in primary care: The HICMan exploratory randomised controlled trial

机译:初级保健中慢性收缩性心力衰竭患者的病例管理:HICMan探索性随机对照试验

获取原文
       

摘要

Background Chronic (systolic) heart failure (CHF) represents a clinical syndrome with high individual and societal burden of disease. Multifaceted interventions like case management are seen as promising ways of improving patient outcomes, but lack a robust evidence base, especially for primary care. The aim of the study was to explore the effectiveness of a new model of CHF case management conducted by doctors' assistants (DAs, equivalent to a nursing role) and supported by general practitioners (GPs). Methods This patient-randomised controlled trial (phase II) included 31 DAs and employing GPs from 29 small office-based practices in Germany. Patients with CHF received either case management (n = 99) consisting of telephone monitoring and home visits or usual care (n = 100) for 12 months. We obtained clinical data, health care utilisation data, and patient-reported data on generic and disease-specific quality of life (QoL, SF-36 and KCCQ), CHF self-care (EHFScBS) and on quality of care (PACIC-5A). To compare between groups at follow-up, we performed analyses of covariance and logistic regression models. Results Baseline measurement showed high guideline adherence to evidence-based pharmacotherapy and good patient self-care: Patients received angiotensin converting enzyme inhibitors (or angiotensin-2 receptor antagonists) in 93.8% and 95%, and betablockers in 72.2% and 84%, and received both in combination in 68% and 80% of cases respectively. EHFScBS scores (SD) were 25.4 (8.4) and 25.0 (7.1). KCCQ overall summary scores (SD) were 65.4 (22.6) and 64.7 (22.7). We found low hospital admission and mortality rates. EHFScBS scores (-3.6 [-5.7;-1.6]) and PACIC and 5A scores (both 0.5, [0.3;0.7/0.8]) improved in favour of CM but QoL scores showed no significant group differences (Physical/Mental SF-36 summary scores/KCCQ-os [95%CI]: -0.3 [-3.0;2.5]/-0.1 [-3.4;3.1]/1.7 [-3.0;6.4]). Conclusions In this sample, with little room for improvement regarding evidence-based pharmacotherapy and CHF self-care, case management showed no improved health outcomes or health care utilisation. However, case management significantly improved performance and key intermediate outcomes. Our study provides evidence for the feasibility of the case management model. Trial registration number ISRCTN30822978
机译:背景技术慢性(收缩期)心力衰竭(CHF)代表一种临床综合征,具有很高的个人和社会疾病负担。案例管理等多方面的干预措施被认为是改善患者预后的有前途的方法,但缺乏可靠的证据基础,尤其是在初级保健方面。该研究的目的是探索由医生助理(DAs,相当于护理角色)并由全科医生(GPs)支持的CHF病例管理新模型的有效性。方法该患者随机对照试验(第二阶段)包括31个DA,并采用了来自德国29个小型诊所的GP。 CHF患者接受了包括电话监控和上门拜访的病例管理(n = 99)或常规护理(n = 100),为期12个月。我们获得了关于一般和特定疾病的生活质量(QoL,SF-36和KCCQ),CHF自我护理(EHFScBS)和护理质量(PACIC-5A)的临床数据,卫生保健利用率数据以及患者报告的数据)。为了在随访时比较各组之间的差异,我们进行了协方差和逻辑回归模型的分析。结果基线测量显示出对循证药物治疗的高度指导依从性和良好的患者自我护理:患者接受血管紧张素转化酶抑制剂(或血管紧张素2受体拮抗剂)的比例分别为93.8%和95%,β受体阻滞剂的比例为72.2%和84%,以及分别有68%和80%的病例同时接受治疗。 EHFScBS分数(SD)为25.4(8.4)和25.0(7.1)。 KCCQ总体总分(SD)为65.4(22.6)和64.7(22.7)。我们发现住院率和死亡率均较低。 EHFScBS评分(-3.6 [-5.7; -1.6])以及PACIC和5A评分(0.5,[0.3; 0.7 / 0.8])均优于CM,但QoL评分无明显组别差异(物理/心理SF-36)摘要分数/ KCCQ-os [95%CI]:-0.3 [-3.0; 2.5] /-0.1 [-3.4; 3.1] /1.7 [-3.0; 6.4])。结论在该样本中,基于证据的药物治疗和CHF自我护理的改善空间很小,病例管理未显示出改善的健康结局或医疗利用率。但是,案例管理显着提高了绩效和关键的中间结果。我们的研究为案例管理模型的可行性提供了证据。试用注册号ISRCTN30822978

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号